Chelly J E, Hysing E S, Hill D C, Abernethy D R, Dlewati A, Doursout M F, Merin R G
Anesthesiology. 1987 Sep;67(3):320-5. doi: 10.1097/00000542-198709000-00007.
To assess the role of both pharmacokinetics and the autonomic nervous system in the interaction between inhalational anesthetics and verapamil, dogs were chronically instrumented to measure heart rate, PR interval, dP/dt, cardiac output, and aortic blood pressure. In a first group of seven dogs, studied awake and during halothane (1.2%), enflurane (2.5%), and isoflurane anesthesia (1.6%), verapamil was infused for 30 min in doses calculated to obtain similar plasma concentrations (83 +/- 10, 82 +/- 6, 81 +/- 10, and 77 +/- 9 ng.ml-1, respectively). For the latter purpose, the infusion dose was 3 and 2 micrograms.kg-1.min-1 awake and during anesthesia, respectively, preceded by a loading dose of 200, 150, and 100 micrograms.kg-1, awake, during isoflurane, and halothane and enflurane, respectively. In awake dogs, verapamil induced an increase in heart rate (24 +/- 5 bpm) and PR interval (35 +/- 9 msec) and a decrease in mean arterial pressure (-5 +/- 2 mmHg) and dP/dt (-494 +/- 116 mmHg/s). Although plasma concentrations were similar in awake and in anesthetized dogs, the only statistically significant changes induced by verapamil were an increase in heart rate and a decrease in dP/dt during halothane and enflurane, while left atrial pressure increased only with enflurane. In a second group of six dogs, verapamil pharmacokinetics were determined in the presence and absence of a ganglionic blocking drug (chlorisondamine, 2 mg.kg-1 iv). Blockade of ganglionic transmission resulted in a decrease in both initial volume of distribution and total clearance of verapamil--changes similar to those previously reported with inhalational anesthetics.(ABSTRACT TRUNCATED AT 250 WORDS)
为评估药代动力学和自主神经系统在吸入麻醉药与维拉帕米相互作用中的作用,对犬进行长期监测以测量心率、PR间期、dp/dt、心输出量和主动脉血压。在第一组7只犬中,分别在清醒状态以及氟烷(1.2%)、恩氟烷(2.5%)和异氟烷麻醉(1.6%)期间,以计算得出的能获得相似血浆浓度(分别为83±10、82±6、81±10和77±9 ng·ml-1)的剂量静脉输注维拉帕米30分钟。为达到此目的,清醒和麻醉期间的输注剂量分别为3和2μg·kg-1·min-1,在清醒、异氟烷、氟烷和恩氟烷麻醉期间,分别先给予200、150和100μg·kg-1的负荷剂量。清醒犬中,维拉帕米可使心率增加(24±5次/分钟)、PR间期延长(35±9毫秒)、平均动脉压降低(-5±2 mmHg)以及dp/dt降低(-494±116 mmHg/s)。尽管清醒和麻醉犬的血浆浓度相似,但维拉帕米仅在氟烷和恩氟烷麻醉期间引起的心率增加和dp/dt降低具有统计学意义,而仅在恩氟烷麻醉时左心房压力升高。在第二组6只犬中,测定了有无神经节阻断药(氯异吲哚铵,2 mg·kg-1静脉注射)时维拉帕米的药代动力学。神经节传递阻断导致维拉帕米的初始分布容积和总清除率均降低——这些变化与先前吸入麻醉药的报道相似。(摘要截选至250词)